- 10/28/2020
- eisai to present latest data on pipeline assets in the area of alzheimer’s disease and dementia at the 13th clinical trials on alzheimer’s disease conference
- 10/27/2020
- global coalition for adaptive research, amgen, and eisai announce first patient enrolled in international covid-19 trial
- 10/26/2020
- eisai and cogstate expand agreement for global development and commercialization of digital cognitive assessment technologies
- 10/21/2020
- notice regarding biogen’s disclosure about the submission of marketing authorization application to european medicines agency for aducanumab for alzheimer’s disease
- 10/16/2020
- supplementary new drug applications for anti-epileptic drug fycompa® as monotherapy for partial-onset seizures, pediatric indication for partial-onset seizures accepted in china
- 10/08/2020
- the university of tokyo and eisai announce research collaboration for the development and drug discovery of targeted protein degradation technology
- 10/06/2020
- industry-academia-government joint development agreement aiming for drug discovery for covid-19 utilizing eritoran and e6011 concluded, non-clinical research activities commence
- 09/30/2020
- eisai and seikagaku enter into agreement for the marketing alliance of si-613, a treatment of osteoarthritis, in south korea
- 09/25/2020
- jyseleca® (filgotinib) approved in japan for rheumatoid arthritis
- 09/23/2020
- eisai receives positive opinion from ema’s chmp on use of antiepileptic agent fycompa® in pediatric patients
